Signet Therapeutics founder Haisheng Zhang is betting on organoids and AI to outsmart diffuse gastric cancer and the limits of traditional “clean” drug design.
Signet Therapeutics founder Haisheng Zhang is betting on organoids and AI to outsmart diffuse gastric cancer and the limits of traditional “clean” drug design.
Changchung Genescience Pharmaceutical Co. Ltd., reported effects of the bispecific antibody-drug conjugate (ADC) of Gensci-143, is in metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors.
Advanced gastric cancer continues to pose a significant medical challenge because of the scarcity of effective treatments and the frequent development of resistance to available drugs.
At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Frontier Medicines Corp. presented a first-in-class covalent activator of p53 Y220C with high potency and selectivity in restoring p53 tumor suppressor function.
The overexpression of fibroblast growth factor receptor 2b (FGFR2b) is tied to tumor progression in several malignancies, such as cholangiocarcinoma, HER2-negative gastric cancer and breast cancer. Lunan Pharmaceutical Group Corp. has developed a novel IgG1 monoclonal antibody against FGFR2b, LNF-2102, for the potential treatment of cancer.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has divulged antibody-drug conjugates (ADCs) potentially useful for the treatment of cancer. The ADCs comprise an antibody or antigen-binding fragment linked to a cytotoxic drug through a linker.
The U.S. FDA has granted orphan drug designation to Dewpoint Therapeutics Inc.’s DPTX-3186, its first-in-class condensate modulator for the treatment of gastric cancer. The designation follows the recent opening of Dewpoint’s IND application for DPTX-3186 earlier in October, and is the first orphan designation ever granted to a condensate-modulating therapeutic.
Various derivatives of α-D-tocopherol (vitamin E) have shown antitumor potential by inhibiting metabolic processes in mitochondria, which nevertheless raises the risk of systemic toxicity. In an approach designed to inhibit such processes in a more targeted fashion, researchers at Yonsei University College of Medicine prepared from α-D-tocopherol a malonate derivative and a primary amide.
Takeda Pharmaceutical Co. Ltd. agreed to codevelop and commercialize up to three of Innovent Biologics Co. Ltd.’s immuno-oncology (I-O) and antibody-drug conjugate (ADC) candidates with the signing of a $11.4 billion deal, including $1.2 billion paid up front.
